This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about ATTR-CM and uncover the differences between hereditary and Wild-type ATTR-CM

Learn about the red flags that may raise suspicion of and techniques used to diagnose ATTR-CM

Explore a range of educational resources to support the diagnosis of ATTR-CM

Click here for Vyndaqel®▼ (tafamidis) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Virtual events

Register now to view recently CPD-accredited on-demand content from the ARiA 2020 E-meeting Series: Advances and Research in ATTR amyloidosis.

In the spirit of this rapidly evolving area, and upon reflection of the current clinical and travel challenges, we are pleased to provide recordings from the virtually delivered, ARiA 2020 E-meeting Series. Between September-December 2020, we were joined by an international faculty of leading experts in the field of ATTR amyloidosis in the presentation and discussion of the following topics:

For each video watched, 1 CPD (Continuing Professional Development) point hour is gained. To earn CPD points, visit this site and select the content you wish to view.

Once the video has been viewed, you will have the option to download the CPD certificate.​​​​​

E-meeting 1: Chair- Isabel Conceição (Portugal)​​​​​​​
Suspicion and diagnosis of ATTR amyloidosis

E-meeting 2: Chair- Pablo Garcia-Pavia (Spain)​​​​​​​
A new era for ATTR amyloidosis 

E-meeting 3: Chair- Laura Obici (Italy) ​​​​​​​
ATTR-CM: Diagnosis in practice 

E-meeting 4: Chair- Claudio Rapezzi (Italy)​​​​​​​
Looking to the future for patients with ATTR-CM 

Sign in / Register here

Explore more

See other educational resources available

Explore more

PP-VYN-GBR-0891. October 2021

Quick Links

Register to receive tailored marketing information from Pfizer by email

Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.

PP-PFE-GBR-2809. October 2020

Sign up now

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020